Research.Patient.info
Recurrent Acute Myeloid Leukemia research hub
2 indexed studies · 0 currently recruiting
- active not recruitingPHASE2
Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation
This study looks at a new drug, enasidenib, for children and young people (aged 2-21) with a type of blood cancer called Acute Myeloid Leukemia (AML) that has come back or is hard to treat. It focuses on those with a specific genetic change in their cancer cells.
United States · Canada - ongoing, recruitingPhase I and Phase II (Integrated)- Other
AML-NET : Acute Myeloid Leukemia treated with with NETrin Abs in combination with [AZACITIDINE + VENETOCLAX]
This study is looking at a new medicine called NETrin Abs, combined with two existing drugs, azacitidine and venetoclax. It's for people with a type of blood cancer called Acute Myeloid Leukaemia (AML) that hasn't responded to previous treatments.
France